- Home
- NEOV vs IGMS Comparison
NEOV vs IGMS Comparison
Compare NEOV & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- IGMS
- Stock Information
- Founded
- NEOV 2018
- IGMS 1993
- Country
- NEOV United States
- IGMS United States
- Employees
- NEOV N/A
- IGMS N/A
- Industry
- NEOV Industrial Machinery/Components
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- NEOV Miscellaneous
- IGMS Health Care
- Exchange
- NEOV Nasdaq
- IGMS Nasdaq
- Market Cap
- NEOV 72.2M
- IGMS 82.1M
- IPO Year
- NEOV N/A
- IGMS 2019
- Fundamental
- Price
- NEOV $3.09
- IGMS $1.17
- Analyst Decision
- NEOV Strong Buy
- IGMS Hold
- Analyst Count
- NEOV 1
- IGMS 8
- Target Price
- NEOV $7.50
- IGMS $6.00
- AVG Volume (30 Days)
- NEOV 160.7K
- IGMS 211.8K
- Earning Date
- NEOV 05-09-2025
- IGMS 08-13-2025
- Dividend Yield
- NEOV N/A
- IGMS N/A
- EPS Growth
- NEOV N/A
- IGMS N/A
- EPS
- NEOV N/A
- IGMS N/A
- Revenue
- NEOV $4,255,136.00
- IGMS $2,681,000.00
- Revenue This Year
- NEOV $208.50
- IGMS $134.30
- Revenue Next Year
- NEOV $128.75
- IGMS $22.37
- P/E Ratio
- NEOV N/A
- IGMS N/A
- Revenue Growth
- NEOV 52.64
- IGMS 27.36
- 52 Week Low
- NEOV $1.80
- IGMS $0.92
- 52 Week High
- NEOV $6.11
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- NEOV 47.07
- IGMS 42.70
- Support Level
- NEOV $2.80
- IGMS $1.17
- Resistance Level
- NEOV $3.04
- IGMS $1.40
- Average True Range (ATR)
- NEOV 0.24
- IGMS 0.07
- MACD
- NEOV -0.04
- IGMS -0.01
- Stochastic Oscillator
- NEOV 17.65
- IGMS 4.17
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.